experimental group:DC-CIK cell therapy

3 trials

Sponsors

Fujian Cancer Hospital

Conditions

Pancreatic CancerPrimary Hepatocellular CarcinomaRenal and Urothelial Carcinoma

Early Phase 1

Phase Ib clinical study on the safety of DC-CIK cell immunotherapy in patients with primary liver cancer after operation

RecruitingChiCTR1900022714

Fujian Cancer HospitalPrimary Hepatocellular Carcinoma

Start: 2019-12-01Updated: 2020-05-25

Phase Ib clinical study on the safety of DC-CIK cell immunotherapy in patients with renal and urothelial carcinoma after operation

RecruitingChiCTR1900022786

Fujian Cancer HospitalRenal and Urothelial Carcinoma

Start: 2019-12-01Updated: 2020-05-25

Phase Ib clinical study on the safety of DC-CIK cell immunotherapy in patients with pancreatic cancer after operation

RecruitingChiCTR1900022787

Fujian Cancer HospitalPancreatic Cancer

Start: 2019-12-01Updated: 2020-05-25